Cargando…

Addition of the mammalian target of rapamycin inhibitor, everolimus, to consolidation therapy in acute myeloid leukemia: experience from the UK NCRI AML17 trial

As part of the UK NCRI AML17 trial, adult patients with acute myeloid leukemia in remission could be randomized to receive the mammalian target of rapamycin inhibitor everolimus, sequentially with post-induction chemotherapy. Three hundred and thirty-nine patients were randomised (2:1) to receive ev...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burnett, Alan K, Das Gupta, Emma, Knapper, Steve, Khwaja, Asim, Sweeney, Marion, Kjeldsen, Lars, Hawkins, Timothy, Betteridge, Sophie E, Cahalin, Paul, Clark, Richard E, Hills, Robert K, Russell, Nigel H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6165825/ https://www.ncbi.nlm.nih.gov/pubmed/29976746 http://dx.doi.org/10.3324/haematol.2018.189514

Ejemplares similares

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
por: Freeman, Sylvie D., et al.
Publicado: (2023)

P503: A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES
por: Potter, Nicola, et al.
Publicado: (2023)

A comparison of FLAG-Ida and daunorubicin combined with clofarabine in high-risk acute myeloid leukaemia: data from the UK NCRI AML17 Trial
por: Burnett, A K, et al.
Publicado: (2018)

A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: the UK NCRI AML19 trial
por: Othman, Jad, et al.
Publicado: (2023)

S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL
por: Knapper, Steven, et al.
Publicado: (2023)

Outcomes of older patients aged 60 to 70 years undergoing reduced intensity transplant for acute myeloblastic leukemia: results of the NCRI acute myeloid leukemia 16 trial
por: Russell, Nigel H., et al.
Publicado: (2021)

Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center
por: Walter, Roland B., et al.
Publicado: (2014)

P484: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL
por: Russell, Nigel, et al.
Publicado: (2023)

The Addition of Arsenic Trioxide to Low Dose Ara-C in Older Patients with AML Does Not Improve Outcome
por: Burnett, Alan K, et al.
Publicado: (2011)

Cancer Informatics in the U.K.: The NCRI Informatics Initiative
por: Reddington, Fiona, et al.
Publicado: (2007)

AML consolidation therapy: timing matters
por: Reimann, Adrian-Manuel, et al.
Publicado: (2023)

Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor‐Naïve Advanced Pancreatic Neuroendocrine Tumors
por: Salazar, Ramon, et al.
Publicado: (2017)

P1677: DEFINING KEY QUALITY OF LIFE METRICS IN ACUTE MYELOID LEUKAEMIA AND HIGH RISK MYELODYSPLASTIC SYNDROME PATIENTS ENROLLED IN LARGE-SCALE UK NCRI AML TRIALS
por: Krishnamurthy, Pramila, et al.
Publicado: (2023)

Everolimus, a mammalian target of rapamycin inhibitor, ameliorated streptozotocin-induced learning and memory deficits via neurochemical alterations in male rats
por: Fanoudi, Sahar, et al.
Publicado: (2018)

Suppression of Allograft Fibrosis by Regulation of Mammalian Target of Rapamycin-Related Protein Expression in Kidney-Transplanted Recipients Treated with Everolimus and Reduced Tacrolimus
por: Nishioka, Shun, et al.
Publicado: (2021)

The cytotoxic T cell proteome and its shaping by mammalian Target of Rapamycin
por: Hukelmann, Jens L., et al.
Publicado: (2015)

Everolimus is better than rapamycin in attenuating neuroinflammation in kainic acid-induced seizures
por: Yang, Ming-Tao, et al.
Publicado: (2017)

Expression of CD200 on AML blasts directly suppresses memory T-cell function
por: Coles, S J, et al.
Publicado: (2012)

The Challenge of AML in Older Patients
por: Burnett, Alan K
Publicado: (2013)

Defining the Optimal Total Number of Chemotherapy Courses in Younger Patients With Acute Myeloid Leukemia: A Comparison of Three Versus Four Courses
por: Burnett, Alan K., et al.
Publicado: (2021)

Selected Abstracts from the 2018 NCRI Cancer Conference of National Cancer Research Institute
Publicado: (2018)

Selected Abstracts from the 2019 NCRI Cancer Conference of National Cancer Research Institute
Publicado: (2019)

Rheb and mammalian target of rapamycin in mitochondrial homoeostasis
por: Groenewoud, Marlous J., et al.
Publicado: (2013)

ncRI: a manually curated database for experimentally validated non-coding RNAs in inflammation
por: Wang, Shuyuan, et al.
Publicado: (2020)

Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation
por: Leal, Rita, et al.
Publicado: (2017)

Investigation of the effects of mTOR inhibitors rapamycin and everolimus in combination with carboplatin on canine malignant melanoma cells
por: Bernard, Sarah, et al.
Publicado: (2021)

Inhibition of mammalian target of rapamycin by rapamycin increases the radiosensitivity of esophageal carcinoma Eca109 cells
por: ZHANG, DEJUN, et al.
Publicado: (2014)

Mammalian target of rapamycin complex 2 regulates inflammatory response to stress
por: Mascarenhas, Desmond, et al.
Publicado: (2012)

Rapamycin Pretreatment Rescues the Bone Marrow AML Cell Elimination Capacity of CAR-T Cells
por: Nian, Zhigang, et al.
Publicado: (2021)

Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2011)

SIRT1 Negatively Regulates the Mammalian Target of Rapamycin
por: Ghosh, Hiyaa Singhee, et al.
Publicado: (2010)

Mammalian target of rapamycin signaling in diabetic cardiovascular disease
por: Chong, Zhao Zhong, et al.
Publicado: (2012)

Driving neural regeneration through the mammalian target of rapamycin
por: Maiese, Kenneth
Publicado: (2014)

Therapeutic control of leishmaniasis by inhibitors of the mammalian target of rapamycin
por: Khadir, Fatemeh, et al.
Publicado: (2018)

Autism Spectrum Disorder and Mammalian Target of Rapamycin System
por: Posar, Annio, et al.
Publicado: (2020)

Crosstalk of the Caspase Family and Mammalian Target of Rapamycin Signaling
por: Yan, Junfang, et al.
Publicado: (2021)

Assessing the role of everolimus in reducing hepatocellular carcinoma recurrence after living donor liver transplantation for patients within the UCSF criteria: re-inventing the role of mammalian target of rapamycin inhibitors
por: Thorat, Ashok, et al.
Publicado: (2017)

Everolimus Reverses Palbociclib Resistance in ER+ Human Breast Cancer Cells by Inhibiting Phosphatidylinositol 3-Kinase(PI3K)/Akt/Mammalian Target of Rapamycin (mTOR) Pathway
por: Chen, Lin, et al.
Publicado: (2019)

Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma
por: Jin, Hong-Guang, et al.
Publicado: (2018)

Rapamycin protects against aristolochic acid nephropathy in mice by potentiating mammalian target of rapamycin-mediated autophagy
por: Lin, Fan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1aehqnmc8ulvorkgr0p9hmhfri